Table 1.
Demographic and baseline characteristics
| Characteristic | All patients (N = 83) |
|---|---|
| Age, median (range), years | 70 (47–88) |
| Male, n (%) | 60 (72.3) |
| White, n (%) | 73 (88.0) |
| FVC, mean (SD), percent predicted | 67.7 (18.7) |
| DLco, mean (SD), percent predicted | 38.0 (13.4) |
| Supplemental O2 use, n (%) | 42 (50.6) |
| Concomitant medications of interest, n (%)a | |
| Prednisone | 53 (63.9) |
| Acetylcysteine | 26 (31.3) |
| Azathioprine | 10 (12.0) |
| Comorbidities of interest, n (%) | |
| Gastroesophageal reflux disease | 43 (51.8) |
| Cardiac disorders | 28 (33.7) |
| Pulmonary hypertension | 7 (8.4) |
| Type 2 diabetes mellitus | 6 (7.2) |
| Emphysema | 4 (4.8) |
| Time from IPF or PF diagnosis to first dose, median (range), years | 2.7 (0.7–9.6) |
DLco diffusing capacity for carbon monoxide, FVC forced vital capacity, IPF idiopathic pulmonary fibrosis, O2 oxygen, PF pulmonary fibrosis
aA total of 9 patients (10.8%) received combination therapy of prednisone, acetylcysteine, and azathioprine during the PIPF-002 study